research Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
Search
for
Sort by
Research
210-240 / 1000+ results 
research Tratamiento con tofacitinib en adolescentes con alopecia areata
Tofacitinib treatment is used for teenagers with alopecia areata.
research Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
Upadacitinib improved multiple immune-related conditions in one patient.
research Tofacitinib: A Promising Treatment for Adolescent Alopecia Areata
Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.
research Successful treatment of alopecia universalis with abrocitinib: a case report
Abrocitinib may effectively treat stubborn alopecia universalis.
research Upadacitinib for the management of severe alopecia areata in adolescent patients: a single-centre retrospective study
Upadacitinib is effective and safe for treating severe alopecia areata in teens.
research Insulin sensitivity, androgens and isotretinoin therapy in women with severe acne
Isotretinoin improves severe acne without changing androgen or insulin levels but may increase body weight and triglycerides.
research Randomised controlled study for comparing the efficacy of tretinoin 0.05% cream alone versus tretinoin combined with microdermabrasion in adult patients of alopecia areata
Tretinoin alone is more effective than combined with microdermabrasion for long-term alopecia areata treatment.
research Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo
Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
research Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review
Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.
research Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients
Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
research Efficacy and safety of tofacitinib in pediatric patients with alopecia areata: A prospective cohort study
Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
research Dermatological drugs, topical agents, and cosmetics
Tretinoin gel is safe for sun exposure, but tacalcitol doesn't significantly improve non-segmental vitiligo.
research Alopecic Scalp Cysts Following Isotretinoin
Isotretinoin can cause rare scalp cysts and hair loss, treatable with medication.
research Effective Treatment of Folliculitis Decalvans With a Combination of Oral Isotretinoin and Rifampicin
Combining oral isotretinoin and rifampicin effectively treats folliculitis decalvans.
research Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers
A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
research Report of a patient with acne conglobata and perifolliculitis capitis abscedens et suffodiens
A patient with a rare scalp condition showed improvement with isotretinoin and other medications.
research A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol
Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
research Polymer conjugated retinoids for controlled transdermal delivery
A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with less inflammation.
research Therapeutic potential of oral tofacitinib in alopecia areata: a retrospective study
Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
research Creatine phosphokinase levels and isotretinoin therapy
Isotretinoin can raise CPK levels, so patients need monitoring, especially before surgery.
research USE OF TOFACITINIB IN DIFFICULT TO TREAT CLINICALLY AMYOPATHIC DERMATOMYOSITIS
Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
research Keratosis follicularis spinulosa decalvans and acne keloidalis nuchae
A man with scalp and neck skin issues improved after a year of oral isotretinoin.
research Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta‐analysis
Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
research 694 Retinoid induced changes in the fatty acid profile of sebum and its effect on bacterial growth
Retinoids change the fat content in skin oil and reduce bacteria growth, helping to treat acne.
research Abstracts
Oral spironolactone and isotretinoin are effective for treating acne.
research Tofacitinib for the treatment of severe alopecia areata and variants: A retrospective cohort study of 90 patients
Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
research Heat Enhanced Follicular Delivery of Isotretinoin to the Skin
Applying heat with certain chemicals can greatly improve how well isotretinoin gets into the skin through hair follicles.
research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research Upadacitinib Efficacy for the Treatment of Concomitant Psoriasis and Alopecia Areata
Upadacitinib effectively treated a patient with multiple inflammatory conditions.